Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Selinexor, Cyclophosphamide and Prednisone in Relapsed or Refractory Multiple Myeloma
NCT06212596Phase 2Completed
- Sponsor
- University of Leeds
- Start
- Jul 2018
- Primary completion
- Oct 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of selinexor in multiple myeloma (MM), sponsored by University of Leeds. Started Jul 2018; status: completed.
02
Drugs
selinexor
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT06212596.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06212596.